Drugs / almorexant
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT01954589 | Nov 2011 → Jan 2012 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01987739 | Sep 2009 → Feb 2010 | — | Midnight Pharma, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00640848 | May 2006 → Aug 2007 | insomnia | Midnight Pharma, LLC | Completed | Met primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00606593 | Dec 2007 → Apr 2008 | insomnia | Midnight Pharma, LLC | Completed | Met primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00608985 | Mar 2008 → Sep 2009 | insomnia | Midnight Pharma, LLC | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT01243060 | May 2011 → Jul 2014 | — | Northern California Institute of Research and Education | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | almorexant | “Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia” NCT00606593 ↗ |
| Known as | ACT-078573 | “Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia” NCT00606593 ↗1“Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia” NCT00608985 ↗ |
| Action | Inhibit | “dual OX1R and OX2R antagonist” PMID 28735928 ↗ May 2017 |
| Modality | Small molecule | — CHEMBL455136 ↗ |
| Route | Oral | “oral administration of almorexant” NCT00608985 ↗ |